NaviFUS among Final Contestants for Taipei Biotech Award, Makes Progress in Clinical Trials

by NaviFUS
in 2019
on 26/07/2019

NaviFUS qualified for entry into the 2019 Taipei Biotech Awards and will present at the prize-winners’ pavilion during the event at Nangang Exhibition Hall. NaviFUS also announced that the safety study for “Focused Ultrasound-induced Blood Brain Barrier (BBB) Disruption in recurrent Glioblastoma patients” has been completed in June, with the case report to be completed in August. The study was conducted at Linkou Chang Gung Memorial Hospital, and none of the subjects had developed any treatment-related side effects. CEO Dr. Arthur Lung stated that the next step would be to continue towards Proof-of-Concept phase study, and he expressed that this project would be a major proponent of NaviFUS’ product line. NaviFUS has also been conducting a safety study for another epilepsy clinical trial recently at Taipei Veterans General Hospital and has completed its first FIH case in June; the study is currently in the stage of continuing to recruit more patients. Also, continuing its previous collaboration with experts in brain tumors and epilepsy from Stanford University…